Bendigo and Adelaide Bank Posts Strong Q3 Earnings, Announces AI-Driven Job Cuts 
Bill Ackman Eyes New Fund to Bet Against Market Complacency 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
Rio Tinto's California Boron Assets Attract Over a Dozen Bidders, Valued at Up to $2 Billion 
MATCH Act: How New U.S. Chip Legislation Could Freeze China's Semiconductor Ambitions 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
Anthropic Fights Pentagon Blacklisting in Dual Federal Court Battles 
TSMC Posts Strong Q1 2025 Revenue, Riding AI Chip Demand Wave 
Kia Cuts EV Sales Target for 2030 Amid Slowing Demand and U.S. Policy Shifts 
FedEx Pilots and Union Reach Tentative Agreement on 40% Pay Increase 
NIO ES9 SUV Launch Sends HK Shares Down 7% Despite Bold Pricing Strategy 
Abbott Laboratories Ordered to Pay $53 Million in Premature Infant Formula Lawsuit 
Tokyo Electric Power Attracts Major Investors Amid Billion-Dollar Restructuring Push 
U.S. Automakers Push Back Against EU Rules Blocking American Trucks from European Market 
Bank of America Identifies Top Asia-Pacific Semiconductor Stocks Poised for AI-Driven Growth 
OpenAI Addresses Security Vulnerability in macOS App Certification Process 
Chalco Stock Surges as Q1 2025 Profit Forecast Jumps Up to 58% 
SANTA CLARA, Calif., Aug. 22, 2017 -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, announced today the appointment of Dr. Leon Hall as Vice President of Global Scientific Excellence. In his new role, Dr. Hall will be responsible for overseeing global R&D programs and advancing Crown Bioscience’s scientific excellence initiatives.
“Leon’s appointment reinforces Crown Bioscience’s dedication to innovation and commitment to providing the highest quality therapeutic technology services," said Jean-Pierre Wery, Ph.D., Crown Bioscience Chief Executive Officer. "His extensive scientific and operational experience will serve Crown Bioscience well as we expand to meet the growing needs of preclinical research to the global biopharmaceutical market worldwide."
“I am excited about contributing to the expansion of Crown Bioscience’s translational technology platform at a higher level,” said Dr. Hall. “I look forward to continuing Crown Bioscience’s commitment to quality and scientific integrity embedded throughout the global organization.”
Dr. Hall previously served as Crown Bioscience’s Senior Scientific Director and led Crown Bioscience’s Global Scientific Excellence Initiative. Dr. Hall established the Global Quality Council as well as the Global Scientific Councils that govern Crown Bioscience’s research in oncology, immunology, inflammation, cardiovascular and metabolic diseases. His efforts have ensured global standards of excellence, harmonization and fostered collaborations in scientific innovation and R&D.
Leon holds a Ph.D. from the University of Leicester, England, in Molecular Pathology and Toxicology. He has over 15 years of preclinical rodent research experience and is considered an industry leader in the application of humanized mouse models in immunology and immuno-oncology.
About Crown Bioscience Inc.
Crown Bioscience is a global drug discovery and development solutions company providing translational platforms to advance oncology, inflammation and metabolic disease research. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Media Enquiries: Jody Barbeau Crown Bioscience Inc. [email protected]
